Biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (Nasdaq:AZN) on Friday announced the launch of AstraZeneca Direct, an online platform designed to provide eligible US patients with a simple, convenient way to access prescribed medications at a transparent cash price with home delivery.
The service targets patients with chronic conditions, including asthma, diabetes, heart failure, and chronic kidney disease, as well as those seeking flu protection.
From October, patients with prescriptions for AIRSUPRA (albuterol/budesonide) or FARXIGA (dapagliflozin) can purchase these medications directly through the platform for up to 70% off the list price. FLUMIST (Influenza Vaccine Live, Intranasal) will also be available for home delivery.
Joris Silon, US country president at AstraZeneca, said that the platform complements AstraZeneca's existing patient support programmes and provides transparent pricing and convenient access.
The platform will be accessible at AstraZenecaDirect.com starting 1 October 2025.
Early, Evidence-Led Cardiovascular Care Strengthened in High-Risk MENA Regions
Nanomi BV to acquire ophthalmology specialist VISUfarma BV
AstraZeneca launches online platform to expand patient access to medications
Avant Technologies enters joint venture to advance stem cell-based diabetes treatments
Innovent and Ollin report progress in development of OLN324 (IBI324)
Alteogen secures European Commission approval for aflibercept biosimilar EYLUXVI
Eli Lilly and Company's orforglipron outperforms oral semaglutide in Phase 3 ACHIEVE-3 trial
Ascletis presents ASC30 study results at EASD Annual Meeting
Kodiak reports positive APEX data for KSI-101 in macular edema secondary to inflammation